PURPOSE OF REVIEW: There continues to be an inadequate organ supply and lack of effective temporary support, for patients with liver failure. The purpose of this review is to discuss recent progress in the field of orthotopic pig-to-nonhuman primate (NHP) liver xenotransplantation (LXT). RECENT FINDINGS: From 1968 to 2012, survival in pig-to-NHP LXT was limited to 9 days, initially due to hyperacute rejection which has been ameliorated through use of genetically engineered donor organs, but ultimately because of profound thrombocytopenia, thrombotic microangiopathy, and bleeding. Most recently, however, demise secondary to lethal coagulopathy has been avoided with LXT of α(1,3)-galactosyltransferase knockouts and cytomegalovirus-negative porcine xenografts into baboons receiving exogenous administration of coagulation factors and co-stimulation blockade, establishing that a porcine liver is capable of supporting NHP life for nearly a month. SUMMARY: Continued consistent achievement of pig-to-NHP LXT survival beyond 2 weeks justifies consideration of a clinical application as a bridge to allotransplantation for patients with acute hepatic failure. Further genetic modifications to the donor, as well as additional studies, are required in order to apply LXT as destination therapy.
PURPOSE OF REVIEW: There continues to be an inadequate organ supply and lack of effective temporary support, for patients with liver failure. The purpose of this review is to discuss recent progress in the field of orthotopic pig-to-nonhuman primate (NHP) liver xenotransplantation (LXT). RECENT FINDINGS: From 1968 to 2012, survival in pig-to-NHP LXT was limited to 9 days, initially due to hyperacute rejection which has been ameliorated through use of genetically engineered donor organs, but ultimately because of profound thrombocytopenia, thrombotic microangiopathy, and bleeding. Most recently, however, demise secondary to lethal coagulopathy has been avoided with LXT of α(1,3)-galactosyltransferase knockouts and cytomegalovirus-negative porcine xenografts into baboons receiving exogenous administration of coagulation factors and co-stimulation blockade, establishing that a porcine liver is capable of supporting NHP life for nearly a month. SUMMARY: Continued consistent achievement of pig-to-NHP LXT survival beyond 2 weeks justifies consideration of a clinical application as a bridge to allotransplantation for patients with acute hepatic failure. Further genetic modifications to the donor, as well as additional studies, are required in order to apply LXT as destination therapy.
Authors: Jigesh A Shah; Nalu Navarro-Alvarez; Matthew DeFazio; Ivy A Rosales; Nahel Elias; Heidi Yeh; Robert B Colvin; A Benedict Cosimi; James F Markmann; Martin Hertl; David H Sachs; Parsia A Vagefi Journal: Ann Surg Date: 2016-06 Impact factor: 12.969
Authors: Y Luo; S Kosanke; L Mieles; T Kobayashi; S F Li; M Niekrasz; A Shimizu; Y Ye; R B Colvin; D K Cooper Journal: Xenotransplantation Date: 1998-08 Impact factor: 3.907
Authors: Rafael Bañares; Frederik Nevens; Fin Stolze Larsen; Rajiv Jalan; Agustín Albillos; Matthias Dollinger; Faouzi Saliba; Tilman Sauerbruch; Sebastian Klammt; Johann Ockenga; Albert Pares; Julia Wendon; Tanja Brünnler; Ludwig Kramer; Philippe Mathurin; Manuel de la Mata; Antonio Gasbarrini; Beat Müllhaupt; Alexander Wilmer; Wim Laleman; Martin Eefsen; Sambit Sen; Alexander Zipprich; Teresa Tenorio; Marco Pavesi; Hartmut H-J Schmidt; Steffen Mitzner; Roger Williams; Vicente Arroyo Journal: Hepatology Date: 2013-02-15 Impact factor: 17.425
Authors: R Y Calne; D R Davis; J R Pena; H Balner; M de Vries; B M Herbertson; P R Millard; V C Joysey; M J Seaman; J R Samuel; J Stibbe; D L Westbroek Journal: Lancet Date: 1970-01-17 Impact factor: 79.321
Authors: P Ramirez; R Chavez; M Majado; V Munitiz; A Muñoz; Q Hernandez; C G Palenciano; G Pino-Chavez; M Loba; A Minguela; J Yelamos; M R Gago; A S Vizcaino; H Asensi; M G Cayuela; B Segura; F Marin; A Rubio; T Fuente; R Robles; F S Bueno; T Sansano; F Acosta; J M Rodriguez; F Navarro; J Cabezuelo; E Cozzi; D J White; R Y Calne; P Parrilla Journal: Transplantation Date: 2000-10-15 Impact factor: 4.939
Authors: N Navarro-Alvarez; J A Shah; A Zhu; J Ligocka; H Yeh; N Elias; I Rosales; R Colvin; A B Cosimi; J F Markmann; M Hertl; D H Sachs; P A Vagefi Journal: Am J Transplant Date: 2016-02-05 Impact factor: 8.086
Authors: Robert J Fontana; Caitlyn Ellerbe; Valerie E Durkalski; Amol Rangnekar; Rajender K Reddy; Todd Stravitz; Brendan McGuire; Timothy Davern; Adrian Reuben; Iris Liou; Oren Fix; Daniel R Ganger; Raymond T Chung; Mike Schilsky; Steven Han; Linda S Hynan; Corron Sanders; William M Lee Journal: Liver Int Date: 2014-07-28 Impact factor: 5.828
Authors: L Makowa; D V Cramer; A Hoffman; M Breda; L Sher; G Eiras-Hreha; P J Tuso; C Yasunaga; C A Cosenza; G D Wu Journal: Transplantation Date: 1995-06-27 Impact factor: 4.939
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath Journal: Nat Commun Date: 2016-04-05 Impact factor: 14.919